UNITY Biotechnology (UBX)
(Delayed Data from NSDQ)
$1.45 USD
+0.01 (0.69%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.45 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for UNITY Biotechnology, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 43 | 95 | 88 | 98 | 122 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 2 | 2 | 3 | 8 |
Total Current Assets | 47 | 97 | 91 | 101 | 129 |
Net Property & Equipment | 5 | 8 | 10 | 13 | 17 |
Investments & Advances | 0 | 0 | 2 | 18 | 3 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 2 |
Total Assets | 66 | 124 | 125 | 156 | 151 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 2 | 3 | 5 |
Current Portion Long-Term Debt | 0 | 9 | 3 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 8 | 10 | 12 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 1 | 0 | 1 |
Total Current Liabilities | 8 | 20 | 17 | 14 | 17 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 11 | 18 | 25 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 0 | 0 | 0 | 13 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 37 | 58 | 65 | 73 | 31 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 513 | 527 | 460 | 422 | 367 |
Retained Earnings | -484 | -460 | -400 | -339 | -245 |
Other Equity | 0 | 0 | 0 | 0 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 28 | 67 | 60 | 83 | 121 |
Total Liabilities & Shareholder's Equity | 66 | 124 | 125 | 156 | 151 |
Total Common Equity | 28 | 67 | 60 | 83 | 121 |
Shares Outstanding | 16.70 | 14.10 | 5.70 | 5.20 | 4.50 |
Book Value Per Share | 1.70 | 4.74 | 10.45 | 15.94 | 26.82 |
Fiscal Year End for UNITY Biotechnology, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 34 | 36 | 43 | 46 | 69 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 3 | 4 | 4 |
Total Current Assets | 36 | 39 | 47 | 50 | 73 |
Net Property & Equipment | 5 | 5 | 5 | 5 | 7 |
Investments & Advances | 0 | 2 | 0 | 0 | 2 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 54 | 59 | 66 | 69 | 101 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 14 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 6 | 6 | 7 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 9 | 8 | 8 | 9 | 22 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 4 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 6 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 34 | 35 | 37 | 33 | 52 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 515 | 514 | 513 | 535 | 533 |
Retained Earnings | -495 | -490 | -484 | -498 | -483 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 20 | 24 | 28 | 36 | 49 |
Total Liabilities & Shareholder's Equity | 54 | 59 | 66 | 69 | 101 |
Total Common Equity | 20 | 24 | 28 | 36 | 49 |
Shares Outstanding | 16.70 | 16.70 | 16.70 | 14.60 | 14.30 |
Book Value Per Share | 1.18 | 1.44 | 1.70 | 2.48 | 3.46 |